BeyondSpring Inc. (BYSI) is up 8.34% in the pre-market trading session at the price of $24.93 despite any recent news. BYSI is a global biopharmaceutical company that develops innovative cancer therapies. Their therapies improve clinical outcomes for patients with high unmet medical needs.
BYSI to Participate in the Upcoming September Conferences
On 8th September 2021, BYSI announced that management would participate in two upcoming conferences in September 2021. Morgan Stanley 19th Annual Global Healthcare Conference will be on 14th September 2021 at 11:45 am ET. Management will also be available for 1×1 meetings from 9th to 15th September 2021. R.W. Baird’s 2021 Global Healthcare Conference will hold on 15th September 2021 at 4:55 pm ET. For this conference, management will also be available from 14th to15th September 2021.
BYSI Scheduled Conference Call for Q2 2021 Financial Results
On 7th September 2021, BYSI published that it had scheduled a conference call on 10th September 2021 at 8:00 AM Eastern Time. The management will host a conference call to report its financial results for the second quarter ended 30th June 2021. It will also provide updates on recent corporate events.
Oral Presentation of Phase 3 DUBLIN-3 Data for Lung Cancer Patients
On 31st August 2021, BYSI announced that it had scheduled Medical Oncology 2021 Congress from 16th to 21st September 2021. The late-breaking oral presentation will take place virtually at the European Society. It will present the final intention-to-treat (ITT) data set from the registrational trial of DUBLIN-3 Phase 3 plinabulin. It will also include data about docetaxel vs. docetaxel alone to treat 2nd/3rd line non-small cell lung cancer (NSCLC) patients with EGFR wild type.
CEO of BYSI, Dr. Lan Huang, remarked that the ESMO Congress is the perfect venue to present high-impact clinical oncology findings. They will publish data from their successful DUBLIN-3 study about plinabulin’s ability to improve overall survival in 2nd/3rd line NSCLC patients. The durable anti-cancer benefit of plinabulin is a gateway to developing it as part of immuno-oncology combos in multiple cancer indications. BYSI plans to apply for an NDA in the U.S. and China to use plinabulin in these NSCLC patients. They are grateful to all of their collaborators for helping them to bring plinabulin for cancer patients globally, he added.
Agreement with Jiangsu Hengrui Pharmaceuticals for Plinabulin
On 26th August 2021, BYSI announced a commercialization and co-development agreement with Jiangsu Hengrui. The deal is about plinabulin, an investigational drug candidate. Plinabulin is currently under NDA Priority Review by the U.S. Food and Drug Administration (FDA) and the China National Medical Products Administration (NMPA). This drug is a first-in-class and selective immunomodulating microtubule-binding agent (SIMBA).
